Abstract
Background/Aim: The efficacy of omega-3 supplementation by oral capsule for patients with Crohn's disease (CD) remains controversial. We investigated the safety and efficacy of an omega-3 emulsified formulation. Patients and Methods: Six patients with CD in remission participated in this open-label clinical trial. Patients ingested one bottle (100 ml) of the test formulation (IMARK S®) daily for 28 days. After a 1-month washout period, patients ingested two bottles of the formulation daily for 28 days. Anthropometric and blood tests were performed before and after each intervention. Results: The omega-3 emulsifying formulation was safe with minimal side-effects. Body weight and body-mass index were not altered; however, CD activity index scores tended to decrease after ingested one bottle of formulation. Blood tests revealed no severe adverse effects. Conclusion: Supplementation with an omega-3 emulsifying formulation can be safe and useful for maintaining remission in patients with CD and warrants further studies.
- Crohn's disease
- omega-3 polyunsaturated fatty acid
- maintenance for remission
- dose-finding trial
- safety trial
Footnotes
Conflicts of Interest
Nippon Suisan Kaisha, Ltd. provided the IMARK S® testing formulation. The Department of Integrative Medicine, Osaka University Graduate School of Medicine and the Department of Therapeutics for Inflammatory Bowel Diseases, Osaka University Graduate School of Medicine, are supported by donated funds and are managed by a fund from Amino Up Chemical Co., Ltd and Kinshukai Medical Corporation, respectively. For the remaining authors, no conflicts of interest are declared. The sponsor had no control over the research, writing or publication of this work.
- Received April 5, 2016.
- Revision received May 12, 2016.
- Accepted May 16, 2016.
- Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved